Clobetasol

Generic name
Clobetasol
Brand name
ATC Code
D07AD01
Compare …

Clobetasol

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Phimosis
  • Cutaneous
    • 2 years up to 14 years

      • Apply thinly twice daily. Maximum dose 30 g per 4 weeks. Treatment in combination with retraction of the foreskin.

      • Duration of treatment:

        Treatment for 4 weeks. Treat for a further 4 weeks if necessary.
Steroid-sensitive dermatoses
  • Cutaneous
    • ≥ 1 year

      • Apply 1-2 times daily on affected skin according to finger-tip-unit method.

      • Duration of treatment:

        Max 4 weeks

      • After improvement, reduce the number of applications to once a day or less or continue treatment with a less strong corticosteroid

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

The risk of systemic effects is greatest when: used on children, used under occlusion, used on large areas of skin or skin folds, and used simultaneously with penetration-enhancing medicines (such as salicylic acid, urea, propylene glycol).

In children, the secretion of growth hormone can be suppressed. No systemic or local side effects were reported when using clobetasol in phimosis.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Be cautious when using on children (relatively large skin surface area and thin skin), due to the increased risk of systemic side effects. Prolonged use of particularly potent dermatocorticosteroids in children can lead more quickly to adrenal suppression and also to growth hormone suppression; during prolonged use, it is recommended to regularly monitor height and weight and to determine plasma cortisol levels.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

CORTICOSTEROIDS, PLAIN

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Corticosteroids, weak (group I)
D07AA02
Corticosteroids, moderately potent (group II)
D07AB01
D07AB02
D07AB09
Corticosteroids, potent (group III)
D07AC01
D07AC03
D07AC17
D07AC14
D07AC13
D07AC18

References

  1. van Basten JP, et al, [The use of corticosteroid cream to treat phimosis], Ned Tijdschr Geneeskd, 2003, Aug 9;147(32), 1544-7
  2. GlaxoSmithKline BV, SmPC Dermovate creme RVG 06932 24-5-2018, www.geneesmiddelinformatiebank.nl
  3. Nederlandse Vereniging voor Dermatologie en Venereologie, Multidisciplinaire evidence-based richtlijn Psoriasis, 2017

Changes

Therapeutic Drug Monitoring


Overdose